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Introduction
The Epstein-Barr virus is a fascinating human herpesvirus whose study has provided unique 
insight into host:pathogen interactions and complex cellular molecular processes. The virus 
is the first discovered human tumor virus and was initially identified in primary cell cultures 
of Burkitt lymphoma, an unusual African pediatric lymphoma [1]. The quickly developed 
serologic studies revealed that most people had antibodies to the virus but that patients with 
BL had elevated titers to specific antigenic components [2]. The serologic screenings also 
showed a link between elevated EBV titers and an unusual epithelial nasopharyngeal 
carcinoma (NPC) that developed with extraordinarily high incidence in Southern China [3]. 
The seroconversion of the young technician performing these early serologies following a 
bout with infectious mononucleosis led to definitive serologic studies that proved infectious 
mononucleosis was the disease manifestation associated with primary infection [4].
The continuing studies of EBV have identified additional cancers and diseases linked to 
EBV [5]. An overarching goal has been to define in what way a virus that is carried by 
almost everyone contributes to intriguing and unique cancers. The study of EBV has 
illuminated the molecular biology of latent herpesvirus infection and new potent 
mechanisms through which cell growth can be modulated by viruses. This review will 
summarize key findings that form the basis for our understanding of EBV pathogenesis with 
special emphasis on newly identified potential mechanisms through which EBV alters 
cellular growth.
EBV Biology and Link to Human Cancers
The biologic properties of the virus were immediately intriguing as it was shown that the 
cell lines could be established from BL samples and could produce virus that could infect 
primary B cells with EBV and transform them into immortalized cell lines. This powerful 
molecular phenotype has led to the identification of the viral proteins that are essential for 
latent infection and required for cell transformation [6]. Virus production can be induced in 
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the cell lines where most of infected cells do not produce virus and are considered to be 
latently infected. In latent infection the viral DNA is not usually integrated into the host 
chromosome but rather is stably maintained as an extrachromosomal episome [7]. This was 
the first molecular characterization of the herpesviral genome in cells that represented a 
“latent” or nonpermissive infection and provided a new understanding of how these viruses 
can readily reactivate from latent to permissive infection. The episomal DNA had 
nucleosomal structure and was maintained using a specific origin for plasmid DNA 
replication, orip, that was activated by binding of one of the EBV nuclear antigens (EBNAs) 
[8].
Early studies revealed that in transformed cell lines and within the EBV associated tumors, 
EBV DNA was present in every cell which also contained viral RNAs and proteins. The first 
RNAs to be identified were entitled EBERs (EBV encoded RNA) [9]. These enigmatic 
noncoding RNAs can be present at a million copies per cell but are not required for B-cell 
transformation [10]. Their high stability and abundance have made them a superb marker for 
EBV latent infection and their detection is one criteria for determining the association of 
different tumors with EBV infection. Another criteria is the detection of clonal viral EBV 
genomes. Viral clonality is based on restriction enzyme analysis of the terminal restriction 
enzyme fragments [11]. These fragments are quite heterogeneous due to varying numbers of 
terminal repeats (TR) at each end of the linear genome. In linear, virion DNA the terminal 
restriction enzyme fragments migrate as a ladder array with each band representing a 
fragment with a certain number of TRs and can be identified on Southern blots using a probe 
representing unique DNA from the left or right end of the genome. In the circular episomal 
form the right and left ends of the genome are fused such that the left and right DNA probes 
hybridize to the same fragment. In tumor samples with clonal episomal DNA, a single 
fragment is detected by both probes. If viral replication has reactivated in some cells, faint 
ladder arrays of terminal fragments are detected. The detection of clonal episomes revealed 
that every EBV genome within a cell was identical and suggested by extension that the 
malignant cells were also clonal [11]. This prediction and correlation has been confirmed in 
lymphoid cell lines where immunoglobulin gene rearrangement can be used as a marker of 
cellular clonality.
EBV is now considered an etiologic factor in multiple types of cancer that primarily develop 
in lymphocytes and epithelial cells (Figure 1). These include cancers that develop in the 
immunocompromised such as AIDS-associated lymphomas and post-transplant 
lymphoproliferative disease and also unusual cancers that develop in the immunocompotent 
[5]. Some of the cancers have very distinct patterns of incidence such as BL, NPC, T-cell 
lymphoma, and salivary gland carcinoma. These malignancies develop in specific 
geographic and ethnic populations and environmental, genetic, and immune factors 
potentially contribute. Additionally, EBV is also found in a consistent subset of some 
cancers worldwide including Hodgkin lymphoma and gastric carcinoma.
EBV Transformation and Viral Oncoproteins
Interestingly, differences in viral expression comparing EBV expression in transformed 
lymphocytes to that in tumor samples were identified in early studies. Comparison of 
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sequences encoding polyadenylated RNA from Burkitt lymphoma biopsy material identified 
abundant transcription from specific restriction enzyme fragments that was not detected in 
transformed cell lines [12]. Similar studies of NPC biopsy samples indicated that the 
sequences later shown to encode EBNA2 and EBNA3 were not transcribed in NPC but there 
was abundant transcription of sequences that encode latent membrane proteins 1 and 2 
(LMP1, and LMP2), and the BamHI A restriction fragment (BamHI A rightward transcripts 
- BARTs) [13]. These findings led to the identification of three distinct types of latent 
infection with differing patterns of viral expression. The malignancies and some cell lines 
are characterized by different patterns of viral expression and are classified into types I, II 
and III [14]. Type I latency, typical of Burkitt lymphoma, has the most restricted expression 
profile such that only the EBV nuclear antigen 1 (EBNA1), the untranslated 
nonpolyadenylated EBERs, and variable levels of BART miRNAs are expressed (Figure 1). 
Type II latency is associated with nasopharyngeal carcinoma and Hodgkin lymphoma, with 
expression of (LMP1, LMP2A and LMP2B) in addition to the transcripts expressed in type I 
latency. The BART transcripts and the BART miRNAs are particularly abundant in NPC 
and gastric carcinoma. Expression is the most complex in Type III latency which is 
characteristic of transformed B-cells in culture and is only found in cancers linked to 
immunosuppression such as post-transplant lymphoma and AIDS-associated lymphoma [5].
Molecular analysis of the transformed cell lines maintained in vitro has revealed that 
transformation is dependent upon the carefully regulated expression of the viral genes [6]. 
The EBNA1 protein binds to orip and is required for maintenance of the viral episome and 
its replication by the host cell DNA polymerase machinery [8]. EBNA2, EBNA3A, 3B, 3C, 
and leader protein (LP) regulate transcription of cellular genes and LMP1 and LMP2 
through interactions with the major transcription factor for the NOTCH pathway, RBPJκ 
[15,16]. In addition to being the major transcriptional regulators during latent infection, 
EBNA2 and particularly the EBNA3 proteins are the primary targets of cytotoxic 
lymphocytes. Thus in immunocompromised individuals, the latently infected cells can 
switch into the transforming latency III pattern of expression leading to the development of 
polyclonal and subsequent monoclonal lymphoma. These tumors can respond to reduced 
immunosuppression and can be prevented or eliminated by EBV-specific cytotoxic T-cell 
preparations.
In the immunocompetent, one event that likely contributes to the development of cancer is to 
have more restricted expression of viral proteins with the expression of the viral 
transforming proteins, LMP1 and LMP2 in the absence of the EBNA proteins that are 
recognized by the immune system. In the more restricted infections in Type I or II latency, 
the noncoding miRNAs or EBER RNAs may have increased etiologic contributions.
Latent Membrane Protein 1
Latent membrane protein 1 (LMP1) is considered the major oncogene of EBV as it has 
transforming properties in cultured cell lines and is essential for B-lymphocyte 
transformation [5]. LMP1 transcription is also consistently detected in several of the EBV-
associated cancers including post-transplant lymphoma, Hodgkin Disease (HD), and 
nasopharyngeal carcinoma (NPC). LMP1 functions as a constitutively active member of the 
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tumor necrosis factor receptor family and activates multiple signaling pathways including 
mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK), 
phosphatidylinositol 3-kinase (PI3K)/Akt, and NF-κB. LMP1 induces the expression of 
specific genes that are involved with apoptosis, cell cycle progression, cell proliferation, and 
migration. Inhibition of NF-κB induces apoptosis of EBV transformed cells and fibroblast 
and epithelial cell transformation require activation of PI3kinase/Akt. An additional 
important target of LMP1 is EGFR, a member of the ErbB receptor tyrosine kinase family 
[17]. Thus LMP1 activates a wealth of signaling pathways that could be specifically targeted 
in EBV infected tumors.
Two regions, CTAR1 and CTAR2, have been identified within the cytoplasmic carboxy 
terminal domain that activates NF-κB. C-terminal activating region 2 (CTAR2) activates the 
canonical NF-κB pathway which includes p50/p65 complexes while C-terminal activating 
region 1 (CTAR1) can activate both the canonical and noncanonical pathways to produce 
multiple distinct NF-κB dimers, including p52/p50, p52/p65, and p50/p50 [17]. CTAR1 also 
uniquely upregulates the epidermal growth factor receptor (EGFR) in epithelial cells. 
Increased p50-Bcl-3 complexes have been detected by chromatin precipitation on the NF-κB 
consensus motifs within the egfr promoter in CTAR1-expressing epithelial cells and NPC 
cells [18]. The study of LMP1 activation of NF-κB has been particularly informative for 
determining potential specificities of this important family of transcription factors. Many 
studies have relied on reporter assays to identify NF-κB activation, however, analyses of 
LMP1 mediated activation have led to the identification of canonical and noncanonical 
activation and distinct genes that are regulated by the distinct forms
To explore the possibility that specific EBV variants may be linked to cancer development 
and potentially explain the geographic differences in incidence of some cancers, many 
studies have analyzed EBV variants. To determine if variants of LMP1 existed, perhaps 
analogous to the oncogenes of high risk papillomavirus, analysis of sequence variation 
within LMP1 identified consistent signature amino acids that distinguished at least seven 
variants of LMP1 [19]. The CTAR1 and CTAR2 motifs are highly conserved and 
unchanged in all variants and comparison of the biologic and signaling properties of the 
variants indicated that all of the variants were capable of transforming Rat-1 fibroblasts as 
measured by blockage of contact-inhibited and anchorage-independent growth, and inducing 
homotypic adhesion in EBV-negative B-cells [20]. Interestingly, most of the conserved 
sequence changes in the variants were within known and predicted potential Human 
Leukocyte Antigen (HLA)-restricted epitopes, suggesting a potential immune-modulated 
selection mechanism [19]. All of the variants have been detected in various malignancies, 
however, the CAO/China 1 LMP1 variant is significantly more prevalent in NPC tumors 
from the southern endemic region of China. Functional immune recognition studies have 
shown that the China 1 sequence changes within a strong A2/A24 epitope eliminate 
presentation and these HLA types are among the most prevalent in patients with NPC. 
Although LMP1 induces a relatively weak HLA restricted CTL response, the prevalence of 
strains lacking the strongest LMP1 HLA restricted epitope in NPC tumor samples suggests 
that immune escape of viral oncogenes may be one contributing factor in the development of 
EBV associated cancers (Figure 1).
Raab-Traub Page 4













Latent Membrane Protein 2
The Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A) is important for 
maintenance of latency in infected B lymphocytes and also modulates epithelial cell growth 
[21]. Through its immunoreceptor tyrosine-based activation motif (ITAM) and PY motifs, 
LMP2A is able to block B cell receptor (BCR) signaling, bind BCR-associated kinases, and 
manipulate the turnover of itself and these kinases via a PY-mediated interaction with the 
Nedd4 family of ubiquitin ligases. In B cells, LMP2A provides cell survival signals by 
mimicking B cell receptor signaling and activating Syk through the ITAM domain. The Akt 
pathway is also activated by LMP2A in B-cells and contributes to their survival [22]. In 
epithelial cells, LMP2A has been shown to activate the phosphatidylinositol 3′-OH kinase 
(PI3K)/Akt and β-catenin signaling pathways [23]. These effects block differentiation of 
epithelial cells and in some epithelial cell lines, LMP2A can induce transformation and 
anchorage independence [24] [23].
LMP2 is expressed in NPC and at particularly high levels in HD [5]. Several HLA restricted 
epitopes have been identified in LMP2 with a particularly prevalent epitope presented by 
HLA-0201 expressing individuals [25]. This finding may also underlie the higher risk of 
developing NPC in HLA-A2 as the HLA-A-0201 subtype is rare among Chinese compared 
to other HLA-A2 subtypes. Perhaps, similarly to LMP1, impaired immune presentation and 
recognition of LMP2 is a factor that enables its expression and its potent effects on cell 
growth.
Novel Mechanisms to Modulate Cell Growth
Viral miRNAs
One of the most exciting recent findings in molecular biology has been the identification of 
microRNAs (miRNAs) that mediate another type of regulation of cellular gene expression 
[26]. miRNAs are approximately 22-nucleotide long single stranded RNAs that are closely 
related to small interfering RNAs (siRNAs) [26]. It is thought that most miRNAs inhibit the 
translation of mRNAs by targeting an inhibitory complex to specific mRNAs based on base 
pair complementarity. The first viral miRNAs to be identified were cloned from the 
prototype EBV infected B cell line, B95 [27]. Five miRNAs were identified as being derived 
from the EBV genome, including two from the introns of the BARTs. Three of the miRNAs 
were located near the BHRF1 ORF that encodes a bcl2 homologue. These miRNAs have 
subsequently been shown to only be present in cells in Type 3 latency that express the 
primary EBNA transcript that initiates from the Wp or Cp promoters [28]. Recent studies 
indicate that they make a significant contribution to EBV induced growth transformation 
and strains deleted for their expression are impaired [29].
The majority of the BART sequences are deleted in B95 so to identify likely additional 
miRNAs, subsequent studies cloned and sequenced from Kaposi sarcoma associated 
herpesvirus (KSHV) and EBV coinfected pleural effusion lymphoma (PEL) cell lines and 
NPC tumors [28]. These studies identified at least 44 miRNAs produced from the BART 
transcripts. Some of the miRNAs are directly opposite to several genes involved in 
replication and the EBV DNA polymerase is a target of BART2. However, most of the 
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BART miRNAs do not appear regulate viral genes and most likely function in 
downregulating transcripts from the host cell [30]. Presently, some of the identified targets 
function as tumor suppressors indicating one potential mechanism through which the BART 
miRNAs may contribute to EBV-induced oncogenesis.
Several of the identified miR-BART targets identified contribute to apoptosis and the 
miRNAs in general have anti-apoptotic affects. The BH3-only protein, PUMA, which 
contributes to cytochrome c release from the mitochondria is targeted by miR-BART5 [31]. 
The effects on PUMA by miR-BART5 were also shown using 3′UTR reporter assays and by 
immunoblotting. Microarray analysis looking for transcripts that decreased in abundance in 
cells expressing the BART miRNAs identified another BH3-only protein, Bim, that was 
targeted by multiple BART miRNAs [32]. Bim is considered a tumor suppressor and has 
been shown to be targeted by several oncogenic cellular miRNAs in some cancers. EBV 
miRNA targets have also been identified by immunoprecipitating the RNA-induced 
silencing complex (RISC). This approach identified TOMM22 which is part of the 
mitochondrial pore receptor complex for the proapoptotic protein Bax as a potential target 
for miR-BART16. Additional tumor suppressor genes have also been shown to be targets for 
the BART miRNAs including WIF1 (miR-BART19-3p) and APC (miR-BART7, 19-3p, and 
17-5p. It is thought that the individual miRNAs likely target multiple genes and pathways 
and many additional cellular targets for the EBV miRNAs will likely be identified. The 
effects of the miRNAs will clearly vary considerably between cell lines, cell types, and 
individual cells as a result of differences in their individual abundance, the abundance of 
potential target transcripts, the co-targeting by cellular miRNAs, potential allelic differences 
in target sites, and also structural differences in the mRNA with 3′ UTR shortening a 
characteristic of some cancer cells [30].
A recent study has shown that the EBV negative AGS cell line when infected with a 
recombinant EBV becomes anchorage independent, a hallmark of transformation [33]. The 
cells have very little viral protein expression but express high levels of the BART miRNAs, 
similar to EBV positive gastric cancer (Figure 1). Importantly, microarray analysis revealed 
dramatic changes in expression patterns after infection with EBV with highly significant 
enrichment for previously identified and bioinformatically predicted BART miRNA targets 
in the large numbers of genes that were downregulated. These findings suggest that the 
BART miRNAs, in the absence of expression of the EBV transforming proteins, are major 
contributors to the cellular expression changes and can alter cell growth. Thus the viral 
miRNAs may be an etiologic factor in cancer development in immunocompetent individuals 
that would bypass a requirement for viral protein expression and the consequential 
recognition by the immune system.
Exosomes
Exosomes are small vesicles of unique size and shape that are released from cells and have 
been shown to contain and transfer RNA and proteins including integrin and growth factor 
receptors and immune signaling molecules including MHCI and MHCII, ICAM1 and LFA3 
[34]. Initial studies showed that exosomes containing LMP1 could inhibit monocyte 
proliferation and that NPC cells secreted exosomes that contain LMP1 and galectin 9, a 
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protein that specifically interacted with membrane receptor Tim1 and induced apoptosis in T 
cells [35]. LMP1 induces secretion of exosomes that contain fibroblast growth factor, and 
EGFR into exosomes [36]. The purified exosomes containing LMP1 and EGFR are taken up 
by epithelial, endothelial, and fibroblast cells leading to the activation of ERK and PI3K/Akt 
pathways [37]. It has always been noted that LMP1 is not expressed in all cells within 
tumors and in some cases its expression is barely detectable. However, through exosomes, 
limited expression of viral oncoproteins could alter growth regulation in neighboring and 
distant cells. Additionally, EBV miRNAs are secreted in exosomes and shown to affect 
known targets in recipient cells [38]. Through these effects on secretion of key signaling 
molecules, and viral-encoded proteins and miRNAs, EBV could modulate both the tumor 
microenvironment and also potentially impact the infected host.
Conclusions
The molecular studies of EBV transforming proteins have shown them to be a molecular 
treasure treasure trove that has revealed key regulatory mechanism in critical cell pathways. 
The EBNA proteins have helped clarify Notch regulated signaling and the properties of the 
major Notch DNA binding protein, RBPJκ. LMP1 and its interactions with ubiquitin ligases 
have enabled dissection of NF-κB regulation and led to the identification of canonical, 
noncanonical, and bcl3 mediated targets. Future studies of the effects of EBV on cellular 
processes will likely uncover mechanisms that regulate miRNA synthesis and exosome 
secretion.
Importantly, studies of EBV associated cancers have revealed the multiple ways that EBV 
can alter cell growth. In the absence of immune recognition and control, EBV can mediate 
highly regulated growth transformation with expression of all of its growth inducing 
proteins. In other scenarios, environmental factors may enable expression of the less 
antigenic but potent oncogenes, LMP1 and LMP2. The unfortunate combination of specific 
EBV variants and different HLA types may enable these proteins to go unrecognized and the 
EBV induced proliferating cells to escape immune control. Alternatively, their expression 
may become significantly downregulated, however, the potential expression in a rare cell 
and exosomal delivery of the proteins or activated cellular proteins to many cells may 
induce growth and alter the tumor environment. Finally, in some situations with the right 
levels of expression of cell targets and viral and cellular miRNAs, EBV may alter growth 
without any viral protein expression.
The complex growth inducing potential of EBV may initially seem daunting. However, as 
our understanding increases for these many processes, each mechanism represents a 
potential point for therapeutic targeting. These would include EBV protein-specific 
cytotoxic T-cell immunotherapy, inhibiting critical pathways activated by EBV such as 
NFkB, PI3kinase, EGFR, PKC block the critical activation sites of the EBV oncogenes. 
EBV and other oncogenic viruses have provided target-rich environments to be exploited. 
These findings suggest that the eventual control of virally associated cancers is likely to be 
more accessible than cancers that lack these unique viral targets.
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Factors that contribute to EBV oncogenesis
Variation and reduced viral expression
HLA and Immune recognition of viral proteins
Growth regulation by miRNAs
Exosome transfer of oncogenes and signaling molecules
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